Document resource
Chronic obstructive pulmonary disease (COPD) is mainly treated with bronchodilators (long-acting beta-agonists (LABA) and/or long-acting muscarinic antagonists (LAMA)) to reduce symptoms and exacerbations. Inhaled corticosteroids (ICS) are also frequently used, more recently in the form of single inhaler triple therapy (SITT).1–3 There are numerous established adverse effects of ICS (pneumonia, mycobacterial infection, cataracts, glaucoma, thrush, bruising, osteoporosis, adrenal insufficiency—and the list goes on),4 5 with more potent adverse outcomes (pulmonary embolism, cardiovascular disease, type 2 diabetes) having recently been reported in association with high-dose ICS in asthma.6 7 In view of the potential harms of ICS, the increasingly one-size-fits-all use of SITT in COPD1 8 is a growing concern which must be balanced against the therapeutic benefits of ICS (decreased exacerbations, improved lung function and, perhaps, decreased mortality/cardiovascular events).2 3 9 10